Quarterly UpdatesJul 15, 2026, 07:26 AM
Genmab DARZALEX Q2 2026 Net Sales Total $4.207B
AI Summary
Genmab A/S announced that worldwide net trade sales of DARZALEX (daratumumab), including DARZALEX FASPRO, reached $4,207 million in the second quarter of 2026. Sales in the U.S. accounted for $2,435 million, while the rest of the world contributed $1,772 million. Genmab receives royalties on these worldwide net sales from Johnson & Johnson.
Key Highlights
- DARZALEX net sales for Q2 2026 totaled $4,207 million.
- U.S. net trade sales of DARZALEX were $2,435 million.
- Rest of world net trade sales of DARZALEX were $1,772 million.
- Genmab receives royalties on worldwide net sales from Johnson & Johnson.
Price Impact
More from GMAB